GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Haemonetics Corp (NYSE:HAE) » Definitions » Current Ratio

Haemonetics (Haemonetics) Current Ratio : 2.92 (As of Dec. 2023)


View and export this data going back to 1991. Start your Free Trial

What is Haemonetics Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Haemonetics's current ratio for the quarter that ended in Dec. 2023 was 2.92.

Haemonetics has a current ratio of 2.92. It generally indicates good short-term financial strength.

The historical rank and industry rank for Haemonetics's Current Ratio or its related term are showing as below:

HAE' s Current Ratio Range Over the Past 10 Years
Min: 1.35   Med: 2.65   Max: 3.81
Current: 2.92

During the past 13 years, Haemonetics's highest Current Ratio was 3.81. The lowest was 1.35. And the median was 2.65.

HAE's Current Ratio is ranked better than
52.94% of 867 companies
in the Medical Devices & Instruments industry
Industry Median: 2.74 vs HAE: 2.92

Haemonetics Current Ratio Historical Data

The historical data trend for Haemonetics's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Haemonetics Current Ratio Chart

Haemonetics Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.44 2.20 2.74 1.71 3.06

Haemonetics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.11 3.06 3.38 3.28 2.92

Competitive Comparison of Haemonetics's Current Ratio

For the Medical Instruments & Supplies subindustry, Haemonetics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Haemonetics's Current Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Haemonetics's Current Ratio distribution charts can be found below:

* The bar in red indicates where Haemonetics's Current Ratio falls into.



Haemonetics Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Haemonetics's Current Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Current Ratio (A: Mar. 2023 )=Total Current Assets (A: Mar. 2023 )/Total Current Liabilities (A: Mar. 2023 )
=769.722/251.816
=3.06

Haemonetics's Current Ratio for the quarter that ended in Dec. 2023 is calculated as

Current Ratio (Q: Dec. 2023 )=Total Current Assets (Q: Dec. 2023 )/Total Current Liabilities (Q: Dec. 2023 )
=764.982/261.755
=2.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Haemonetics  (NYSE:HAE) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Haemonetics Current Ratio Related Terms

Thank you for viewing the detailed overview of Haemonetics's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Haemonetics (Haemonetics) Business Description

Traded in Other Exchanges
Address
125 Summer Street, Boston, MA, USA, 02110
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
Executives
Stewart W Strong officer: President, Global Hospital C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Anila Lingamneni officer: EVP, Chief Technology Officer HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Charles J Dockendorff director COVIDIEN LTD., 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Diane M Bryant director 2200 MISSION COLLEGE BLVD, SANTA CLARA CA 95054
Josep Llorens officer: EVP, Global Manufacturing HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Michelle L Basil officer: EVP and General Counsel HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Farris Maryanne Maunsell officer: VP, Chief Accounting Officer C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Roy Galvin officer: President, Global Plasma & BC C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Laurie A. Miller officer: SVP, Human Resources C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Mark W Kroll director PO BOX 23, CRYSTAL BAY MN 55323
Dan Goldstein officer: VP, Corporate Controller HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Christopher Simon, director, officer: President & CEO HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
James Darecca officer: EVP, Chief Financial Officer C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Burke William P. Mr. officer: EVP, Chief Financial Officer HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Lloyd Emerson Johnson director 16737 NEW PROVIDENCE LANE, CHARLOTTE NC 28277